Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Sponsor
The Catholic University of Korea
Study ID
NCT01196559
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
20 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Vinorelbine and Gemcitabine — DRUG
    Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle

Study Details

The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination chemotherapy.

Key Dates

Start date
Jan 31, 2011
Status verified
Feb 2015
Primary completion
Oct 31, 2014
Completion
Oct 31, 2014

Study Design

Enrollment
44 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Vinorelbine and Gemcitabine
    Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks

Primary Outcome Measure

Objective response rate (complete response and partial response) [ Time Frame: 16 weeks ]

Related Studies